

# Downregulation of lncRNA *PVT1* inhibits proliferation and migration of mesothelioma cells by targeting *FOXMI*

YUTARO FUJII, VISHWA JEET AMATYA, KEI KUSHITANI, RUI SUZUKI,  
YUICHIRO KAI, TAKAHIRO KAMBARA and YUKIO TAKESHIMA

Department of Pathology, Graduate School of Biomedical and Health Sciences,  
Hiroshima University, Hiroshima 734-8551, Japan

Received August 13, 2021; Accepted October 12, 2021

DOI: 10.3892/or.2021.8238

**Abstract.** Malignant mesothelioma is a highly aggressive tumor, and an effective strategy for its treatment is not yet available. Long non-coding RNAs (lncRNAs) have been reported to be associated with various biological processes, including the regulation of gene expression of cancer-related pathways. Among various lncRNAs, plasmacytoma variant translocation 1 (*PVT1*) acts as a tumor promoter in several human cancers, but its mechanism of action has not yet been elucidated. Increased *PVT1* expression was identified in ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 mesothelioma cell lines. *PVT1* expression was investigated in mesothelioma cell lines by reverse transcription-quantitative polymerase chain reaction and its functional analysis by cell proliferation, cell cycle, cell migration, and cell invasion assays, as well as western blot analysis of downstream target genes. Knockdown of *PVT1* expression in these cell lines by small interfering RNA transfection resulted in decreased cell proliferation and migration and increased the proportion of cells in the G2/M phase. The results of reverse transcription-quantitative polymerase chain reaction analysis revealed that *PVT1* knockdown in mesothelioma cell lines caused the downregulation of Forkhead box M1 (*FOXMI*) expression, while the results of western blot analysis revealed that this knockdown reduced *FOXMI* expression at the protein level. In addition, combined knockdown of *PVT1* and *FOXMI* decreased the proliferation of mesothelioma cell lines. In conclusion, *PVT1* and *FOXMI* were involved in the proliferation of cancer cells. Therefore, *PVT1-FOXMI* pathways may be considered as candidate targets for the treatment of malignant mesothelioma.

## Introduction

Malignant mesothelioma is a highly aggressive tumor with poor prognosis. It arises from mesothelial cells lining the serous cavities (pleura, pericardium, peritoneum and tunica vaginalis). The incidence of mesothelioma is increasing worldwide due to previous occupational and/or environmental exposure to asbestos (1,2). The incidence of malignant mesothelioma in Japan is predicted to reach a peak between 2030 and 2034. In developing countries, the incidence of this disease is predicted to increase due to the continued use of asbestos (3,4). Currently available treatments have a limited effect on malignant mesothelioma management (5). Therefore, there is a need to identify feasible and effective therapeutic targets.

Non-coding RNAs are RNA molecules that are transcribed from the genome but do not encode proteins. They have been revealed to play structural and functional roles within the cell (6-10). They are primarily grouped into two classes based on transcript size: Small non-coding RNAs and long non-coding RNAs (lncRNAs) (11). Small non-coding RNAs include microRNAs (miRNAs) that function as major regulators of gene expression and complex components of cellular gene expression networks. In contrast to miRNAs, lncRNAs are a class of RNA transcripts that are over 200 nucleotides in length (12). lncRNAs have been associated with various biological processes, including epigenetics, alternative splicing, and nuclear import; additionally, they function as precursors of small non-coding RNAs, and regulators of mRNA decay (13-15). Dysregulated lncRNA expression has been reported in numerous cancers, suggesting that lncRNAs are a newly emerging class of oncogenic and tumor-suppressor genes (16).

Plasmacytoma variant translocation 1 (*PVT1*) is an oncogenic lncRNA located at chromosomal region 8q24 (17). The carcinogenicity of *PVT1* has been identified in various human cancers, including non-small cell lung (18), leukemia (19), hepatocellular (20), colon (21), breast (22), and ovarian cancer (23). Non-coding RNA expression data from Human Transcriptome 2.0 GeneChip Array analysis performed in our previous study revealed increased *PVT1* expression in epithelioid mesothelioma and lung adenocarcinoma (24). In the present study, the biological function of *PVT1* in mesothelioma was elucidated.

---

*Correspondence to:* Dr Yukio Takeshima, Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan  
E-mail: ykotake@hiroshima-u.ac.jp

**Key words:** malignant mesothelioma, long non-coding RNA, plasmacytoma variant translocation 1, FOXMI, small interfering RNA

## Materials and methods

***PVT1* expression database.** Affymetrix mRNA expression subset data were obtained from the Cancer Cell Line Encyclopedia (CCLE) website (data created from <https://www.broadinstitute.org/ccle/> on December 7, 2019). The CCLE project dataset is a compilation of gene expression data from human cancer cell lines (25).

***Mesothelioma cell lines.*** ACC-MESO-1 (Expasy ID: CVCL\_5113) and ACC-MESO-4 (Expasy ID: CVCL\_5114) mesothelioma cell lines were purchased from RIKEN BioResource Research Center (Tsukuba, Japan), and NCI-H2052 (CRL-5915) and NCI-H2452 (CRL-5946) mesothelioma cell lines were purchased from the American Type Culture Collection (ATCC). In addition, two lung adenocarcinoma cell lines, A549 and PC9, purchased from the European Collection of Authenticated Cell Cultures, were also used to confirm *PVT1* expression in lung adenocarcinoma. Cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) medium supplemented with 1% kanamycin, 1% amphotericin B, and 10% fetal bovine serum (FBS; all from Thermo Fisher Scientific, Inc.). Cells were maintained in culture dishes at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub>.

***Transfection of mesothelioma cells.*** *PVT1* small interfering (si)RNA (Lincode Human *PVT1* siRNA - SMARTpool; cat. no. R-029357-00-0005) and its negative control (NC) siRNA (Lincode Non-targeting Pool; cat. no. D-001320-10-05) were purchased from GE Healthcare Dharmacon, Inc. Forkhead box M1 (*FOXM1*) siRNA (*FOXM1* Silencer Select Pre-designed siRNA; cat. no. 4427037 ID# s5248) and its NC siRNA (Silencer Select Negative Control No. siRNA; cat. no. 4390843) were purchased from Thermo Fisher Scientific, Inc. Cells cultured until attaining 70–80% confluency, were transfected with 50 nM of *PVT1*/NC siRNA, 25 nM of *FOXM1*/NC siRNA, or both, using Lipofectamine RNAiMAX (Thermo Fisher Scientific, Inc.) in Opti-Mem Reduced Serum Medium (Thermo Fisher Scientific, Inc.) at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub> according to the manufacturer's recommended protocols. The images of morphological change of the transfected mesothelioma cells were captured at 0 and 72 h using a CKX53 inverted light microscope with a DP21 digital camera (Olympus Corporation).

***Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).*** Mesothelioma cell lines (3x10<sup>5</sup> cells) were transfected with 15 pmol of *PVT1*/NC siRNA or 7.5 pmol of *FOXM1*/NC siRNA in 6-well plates at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub> for 72 h. RNA was extracted from the cells using Maxwell<sup>®</sup> RSC simplyRNA Cells Kit and Maxwell<sup>®</sup> RSC Instrument (both from Promega Corporation) according to the manufacturer's protocols. The extracted RNA was reverse-transcribed with SuperScript IV VILO Master Mix (Thermo Fisher Scientific, Inc.) and amplified using Power Up SYBR Green Master Mix (Thermo Fisher Scientific, Inc.) on an AriaMx Real-Time PCR System (Agilent Technologies, Inc.) according to the manufacturer's recommended protocols. In brief, qPCR was performed with initial

denaturation at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 sec and annealing and elongation at 60°C for 1 min, and a dissociation curve condition from 95°C to 60°C. Relative expression levels were calculated using the comparative 2<sup>-ΔΔC<sub>q</sub></sup> method (26). Expression levels were normalized against those of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primer sequences used for RT-qPCR were as follows: *PVT1* forward, 5'-TGAGAACTGTCCCTTACGTGACC-3' and reverse, 5'-AGAGCACCAAGACTGGCTCT-3'; *FOXM1* forward, 5'-GGAGCAGCGACAGGTTAAGG-3' and reverse, 5'-GTTGATGGCGAATTGTATCATGG-3'; and GAPDH forward, 5'-ACAACCTTTGGTATCGTGGAAGG-3' and reverse, 5'-GCCATCACGCCACAGTTTC-3'.

***Cell proliferation assay.*** Mesothelioma cell lines (3x10<sup>3</sup> cells) were incubated with 1 pmol *PVT1*/NC siRNA or 0.5 pmol *FOXM1*/NC siRNA in 96-well plates at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub> for 3 days. The proliferation rate was determined at 24, 48 and 72 h using 100 μl of 2X Cell Titer-Glo 2.0 reagent (Promega Corporation), which assesses the number of viable cells relative to the ATP level, with a GloMax Explorer microplate reader (Promega Corporation) according to the manufacturer's protocols.

***Cell cycle assay.*** Mesothelioma cell lines (1x10<sup>5</sup> cells) were transfected with 5 pmol *PVT1*/NC siRNA in 24-well plates for 3 days, and subsequently the cells were collected after trypsinization and fixed in 70% ethanol in 15-ml centrifuge tubes at room temperature for ~3 h. After ethanol removal, the cells were stained with 200 μl of Guava Cell Cycle Reagent (Luminex Corporation) at room temperature shielding away from the light for 30 min. The reagent containing propidium iodide discriminates the cells at different stages of the cell cycle by labeling cellular DNA. The labeling signal intensity was evaluated using a Guava EasyCyte Mini flow cytometer (Guava Technologies) according to the manufacturer's protocols. Analysis of raw data was performed with FCS express 5.0 (*De Novo* Software).

***Wound healing assay.*** The migration ability of all four mesothelioma cells was analyzed using a wound scratch assay. Serum starved mesothelioma cell lines grown to 80% confluence were incubated overnight with 5 pmol *PVT1*/NC siRNA in collagen-coated 24-well plates at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub>. Wounds were created by scratching the cells with 1-ml micropipette tips. The wells were washed twice to remove floating cells. Images of the gap area (wound) were captured every 24 h (for ACC-MESO-1 every 12 h) using a CKX53 inverted light microscope equipped with a DP21 digital camera (Olympus Corporation), and the gap area was further analyzed using T Scratch software version 1.0 downloaded from <https://github.com/cselab/TScratch> (27).

***Cell invasion assay.*** BD FluroBlok culture inserts containing 8-μm pores (BD Biosciences) were coated with 100 μl of 10X diluted Geltrex Matrigel (Thermo Fisher Scientific, Inc.) at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub> for 3 h. Mesothelioma cell lines (3x10<sup>4</sup> ACC-MESO-1 cells, and 5x10<sup>4</sup> ACC-MESO-4, CRL-5915, CRL-5946 cells) were incubated with 3 pmol siRNA in 500 μl RPMI-1640 medium (without FBS) in the upper chamber of culture inserts and 750 μl RPMI-1640




Figure 1. (A) Box-whisker plot demonstrating *PVT1* expression in various human cancers from the Cancer Cell Line Encyclopedia project. Mesothelioma cell lines are indicated by the red arrow. (B) Left panel, relative expression of long non-coding RNA *PVT1* as determined by reverse transcription-quantitative PCR in mesothelioma and lung adenocarcinoma cell lines. Right panel, amplification and dissociation curves of *PVT1* expression. *PVT1*, plasmacytoma variant translocation 1.

medium containing 5% FBS in the lower chamber of culture inserts according to the manufacturer's protocols. Cells were incubated at 37°C in a humidified incubator supplied with 5% CO<sub>2</sub> for 72 h (48 h for ACC-MESO-1 cells), and invading cells were stained with addition of 50 μl of 1 μg/ml solution of Hoechst 33324 (Thermo Fisher Scientific, Inc.) at room temperature for 10 min, and subsequently the imaged area of the insert membrane was visualized using a fluorescence microscope. The total number of invading cells was analyzed using the CellProfiler cell imaging software version 2.1.0 downloaded from <https://cellprofiler.org> (28).

**Western blot analysis.** Mesothelioma cell lines (3x10<sup>5</sup> cells) were transfected with 15 pmol *PVT1*/NC siRNA in 6-well plates for 72 h. Cell lysates were obtained from the cells using RIPA Lysis Buffer System (Santa Cruz Biotechnology, Inc.), and total protein was determined with Qubit™ Protein Assay Kit using a Qubit Fluorometer (Thermo Fisher Scientific, Inc.). Total proteins (20 μg) were electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel (SureCast Acrylamide Gel; Thermo Fisher Scientific, Inc.) at 200 V for 40 min and transferred onto polyvinylidene difluoride (PVDF) membranes using a Mini Blot Module (Thermo Fisher Scientific, Inc.) at 20 V for 60 min. Following blocking with 2% bovine serum albumin (Sigma Aldrich; Merck KGaA) in 1X TBS with 0.05% Tween-20 at room temperature for 1 h, the membranes were incubated overnight at 4°C with primary antibodies [anti-FOXM1 rabbit

monoclonal antibody (1:4,000; product no. 20459S) and an anti-GAPDH rabbit monoclonal antibody (1:4,000; product no. 2118S; both from Cell Signaling Technology, Inc.)]. The membranes were then incubated with the anti-rabbit IgG, HRP-linked secondary antibody (1:4,000; cat. no. 7074P2; Cell Signaling Technology, Inc.) at room temperature for 40 min. The membranes were stained with ImmunoStar LD (Wako Pure Chemical Industries) at room temperature for 1 min and images were captured using a c-Digit Blot Scanner (LI-COR). Scanned images were analyzed by Image Studio Digits software version 5.2 (LI-COR Biosciences).

**Statistical analysis.** The experiments were performed at least three times in triplicate. Experimental data are expressed as the mean ± standard deviation. The statistical significance of the difference between two groups was analyzed using unpaired Student's t-test with the default function of Microsoft Excel version 16.53. P<0.05 was considered to indicate a statistically significant difference.

**Results**

*PVT1* expression in mesothelioma and lung adenocarcinoma cell lines. *PVT1* expression was high in mesothelioma and non-small cell cancers, in addition to different human cancers (Fig. 1A). RT-qPCR analysis results revealed that *PVT1* was expressed in all four mesothelioma cell lines and two




Figure 2. (A) Left panel, knockdown of long non-coding RNA *PVT1* expression in siRNA-transfected mesothelioma cell lines as determined by reverse transcription-quantitative PCR. Right panel, amplification curves of *PVT1* expression with dissociation curves. (B) Images demonstrating morphology of mesothelioma cell lines at 0 and 72 h of siRNA transfection. There were no prominent morphological changes between negative control and *PVT1* siRNA-transfected cells. Scale bar, 500  $\mu\text{m}$ . *PVT1*, plasmaeytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control.

lung adenocarcinoma cell lines. Compared with the average *PVT1* expression in the two lung adenocarcinoma cell lines, *PVT1* expression was increased by 1.8-, 1.8-, 2.4-, and 1.8-fold in ACC-MESO-1, ACC-MESO-4, CRL-5915 and CRL-5946 cell lines, respectively (Fig. 1B).

*PVT1* expression is reduced by siRNA transfection. *PVT1* expression was downregulated by >80% following *PVT1* siRNA transfection in all mesothelioma cell lines compared with that

in cells transfected with NC siRNA (Fig. 2A). Morphological changes were not observed in *PVT1* siRNA-transfected mesothelioma cell lines compared with NC siRNA-transfected mesothelioma cell lines (Fig. 2B).

*PVT1* knockdown reduces mesothelioma cell proliferation and increases the G2/M phase of the cell cycle. Knockdown of *PVT1* significantly reduced the proliferation of all mesothelioma cells compared with NC siRNA-transfected cells.




Figure 3. (A) Cell proliferation assay of mesothelioma cell lines transfected with *PVT1* siRNA, and NC siRNA for three days. (B) Cell cycle analysis of four mesothelioma cell lines transfected with *PVT1* siRNA or NC siRNA after three days. (Images in the right panel are representative cell cycle histograms). *PVT1*, plasmacytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control

Following 3 days of treatment, the inhibition of *PVT1* expression significantly reduced the viability of ACC-MESO-1 cells by 22.9%, ACC-MESO-4 cells by 14.8%, CRL-5915 cells by 17.6%, and CRL-5946 cells by 23.3% (Fig. 3A). The proportion of cells in the G2/M phase in the *PVT1* siRNA-transfected mesothelioma cell lines (28.7, 27.4, 21.0

and 30.3% in ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cell lines, respectively) was significantly higher than with the NC siRNA-transfected mesothelioma cell lines (17.5, 15.6, 14.4, and 22.8%). The proportion of cells in the G1 phase in the *PVT1* siRNA-transfected mesothelioma cell lines (49.6, 50.2, 52.5 and 55.0%, in




Figure 4. Migration assay of mesothelioma cells transfected with *PVT1* siRNA or NC siRNA. Panel figures are representative images acquired using a microscope. Scale bar, 1 mm. *PVT1*, plasmacytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control.

ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cell lines, respectively) was significantly lower than with the NC siRNA-transfected mesothelioma cell lines (66.3, 63.2, 68.8 and 61.1%) (Fig. 3B).

*PVT1* knockdown reduces mesothelioma cell migration but not invasion. In the *PVT1* siRNA-transfected cells, the gap area decreased more slowly than in the NC siRNA-transfected cell lines in all four cell lines. The migration of ACC-MESO-1 cells after 24 h of *PVT1* knockdown was reduced by 67.5% and that of ACC-MESO-4, CRL5915, and CRL5946 cell lines after 48 h of *PVT1* knockdown was reduced by 64.2, 26.8 and 27.3%, respectively (Fig. 4). *PVT1* was inhibited by siRNA, but it was not significantly associated with the invasion of all four mesothelioma cell lines (data not shown).

*PVT1* knockdown downregulates *FOXM1* expression. All four mesothelioma cell lines exhibited *FOXM1* expression. *FOXM1* mRNA expression in cells transfected with *PVT1* siRNA compared with cells transfected with NC siRNA was downregulated by 77, 83, 84 and 82% in ACC-MESO1, ACC-MESO4, CRL-5915, and CRL-5946 cell lines, respectively (Fig. 5A). Similarly, *FOXM1* protein was downregulated by 41% in ACC-MESO-1 cells, 35% in ACC-MESO-4 cells, 56% in CRL-5915 cells, and 55% in CRL-5946 cells (Fig. 5B).

*FOXM1* and *PVT1* knockdown reduces mesothelioma cell proliferation. Transfection with either *FOXM1* or *PVT1* siRNA revealed a similar decrease in the proliferation of mesothelioma cells. However, combined *FOXM1* and *PVT1* siRNA transfection further decreased the proliferation of mesothelioma cells. Following 3 days of treatment, *FOXM1* knockdown significantly




Figure 5. (A) FOXM1 expression of PVT1 or NC siRNA transfection as determined by reverse transcription-quantitative PCR. The lower panel reveals amplification curves of PVT1 expression with dissociation curves. (B) FOXM1 expression as determined by western blot analysis in PVT1 or NC siRNA-transfected cells. FOXM1, Forkhead box M1; PVT1, plasmacytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control.




Figure 6. Cell proliferation assay of mesothelioma cell lines transfected with PVT1 siRNA, FOXM1 siRNA and combination of both siRNAs for three days. FOXM1, Forkhead box M1; PVT1, plasmacytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control.




Figure 7. (A) *FOXM1* expression of *PVT1* siRNA, *FOXM1* siRNA and combination of both in siRNA-transfected mesothelioma cell lines as determined by reverse transcription-quantitative PCR. (B) *FOXM1* expression as determined by western blot analysis in *PVT1* siRNA, *FOXM1* siRNA and combination of both in siRNA-transfected mesothelioma cells. *FOXM1*, Forkhead box M1; *PVT1*, plasmacytoma variant translocation 1; siRNA, small interfering RNA; NC, negative control.

reduced the viability of ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cells by 24.8, 19.0, 19.2 and 24.4%, respectively. Furthermore, inhibition of both *PVT1* and *FOXM1* expression significantly reduced the viability of ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cells by 37.9, 35.7, 29.1 and 39.9%, respectively (Fig. 6).

*PVT1* and *FOXM1* knockdown downregulates *FOXM1* expression. Downregulation of *FOXM1* mRNA expression

in cells transfected with combined *PVT1* and *FOXM1* siRNA compared with cells transfected with NC siRNA (86, 88, 80 and 82% in ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cell lines, respectively) was markedly lower than that in cells transfected with *PVT1* siRNA alone (64, 73, 62 and 65%) but similar to that in cells transfected with *FOXM1* siRNA alone (84, 86, 79 and 81%) (Fig. 7A). Downregulation of *FOXM1* protein expression in cells transfected with combined *PVT1* and *FOXM1* siRNA compared with cells transfected with NC siRNA (77, 72, 74 and 75% in ACC-MESO-1, ACC-MESO-4, CRL-5915, and CRL-5946 cell lines, respectively) was lower than that in cells transfected with *PVT1* siRNA alone (39, 30, 54 and 46%) but similar to that in cells transfected with *FOXM1* siRNA alone (72, 65, 70 and 73%) (Fig. 7B).

## Discussion

Malignant pleural mesothelioma (MPM) is an aggressive form of cancer. Patients with malignant mesothelioma are treated with surgery, radiotherapy, chemotherapy, and targeted drug therapy. However, the survival rates of MPM patients remain extremely low, with survival ranging from 5 to 13.2 months (29).

In a previous study, the median survival period did not improve beyond 13-29 months with extended pleurectomy/decortication and 12-22 months with extrapleural pneumonectomy (30). Therefore, feasible and effective therapeutic targets need to be identified. In the present study, the biological function of *PVT1-FOXM1* was investigated as a possible novel target in malignant mesothelioma.

As they regulate gene expression and function at the transcriptional, translational, and post-translational levels, lncRNAs are important in tumor growth and metastasis (31,32). Wright *et al* have previously revealed various dysregulated lncRNAs involved in the pathogenesis of malignant mesothelioma using NCode long noncoding microarrays and their potential to serve as biomarkers in MPM (33). However, the mechanisms of these lncRNAs have not yet been described in detail. Non-coding transcripts from our previous gene expression microarray analysis of malignant mesothelioma and lung adenocarcinoma were extracted and analyzed and numerous upregulated lncRNAs were identified, including *PVT1*, MEG3, and H19 (24). Riquelme *et al* previously suggested that c-Myc and *PVT1* copy number gain may promote a malignant phenotype of mesothelioma with *PVT1*, demonstrating a tendency to upregulate proliferation and inhibit apoptosis (34). The biological functions of *PVT1* in malignant mesothelioma have not been fully established; however, previous studies have revealed that *PVT1* knockdown inhibits cell proliferation and induces apoptosis through suppression of c-Myc in leukemia (19) and breast cancer (22). *PVT1* binds competitively with microRNA-424, which has been reported to increase radiosensitivity by regulating CARM1 in non-small cell lung cancer (18). *PVT1* led to increased proliferation and invasion of glioma (35) and hepatocellular carcinoma (20) by targeting EZH2. In the present study, increased expression of *PVT1* in mesothelioma and lung adenocarcinoma cell lines was revealed by RT-qPCR, and *PVT* expression was revealed to be ~2 times higher in mesothelioma than in lung

adenocarcinoma cell lines. *PVTI* knockdown of mesothelioma cell lines revealed reduced cell proliferation with G2/M arrest and migration.

*FOXMI*, a member of the FOX transcription factor family 1, is associated to cell viability and is considered a key gene in the carcinogenic pathway. Previous studies have indicated that *FOXMI* participates in drug resistance, cancer, and metastasis of cancers (36-38). Several previous studies have demonstrated that *FOXMI* is overexpressed in multiple cancers, such as ovarian (39), colon (40), gastrointestinal (41), and non-small cell lung cancer (42). Increased *FOXMI* expression was also observed in mesothelioma cell lines, and knockdown of mesothelioma cell lines decreased their proliferation.

*PVTI* was revealed to promote tumor progression by interacting with *FOXMI* in ovarian and gastric cancer (43,44). In the present study, it was also revealed that *PVTI* knockdown in mesothelioma cell lines downregulated *FOXMI* expression.

Our study also revealed that *PVTI* knockdown reduced *FOXMI* expression. Furthermore, knockdown of both *FOXMI* and *PVTI* in mesothelioma cell lines demonstrated more reduced proliferation of mesothelioma cell lines compared with knockdown of *PVTI* or *FOXMI* alone. *FOXMI* expression in mesothelioma cell lines with combined *PVTI* and *FOXMI* knockdown was lower than that with *PVTI* knockdown alone. Further studies such as spheroid formations and *in-vivo* experiments which are limited in this study are necessary to clarify the function of *PVTI-FOXMI* in mesothelioma cell lines.

In conclusion, it was revealed in the present study that lncRNA *PVTI* was upregulated in mesothelioma cell lines, and knockdown of *PVTI* decreased the proliferation and migration of mesothelioma cells and downregulated *FOXMI* expression. Furthermore, concurrent knockdown of *FOXMI* and *PVTI* in mesothelioma cell lines demonstrated more reduced proliferation compared with knockdown of *PVTI* or *FOXMI* alone. *PVTI* and *FOXMI* may be considered as candidate targets for the therapy of malignant mesothelioma.

### Acknowledgements

The authors would like to thank Ms Yukari Go and Mr Tatsuya Nakagawa of the Technical Center, Hiroshima University for their excellent technical assistance and Ms Naomi Fukuhara (Department of Pathology, Hiroshima University) for administrative support.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Authors' contributions

YF, VJA and YT designed the study. VJA and YT supervised and facilitated the study. YF, RS, KK, YK and TK performed

the experiments. YF and VJA confirm the authenticity of all the raw data. YF analyzed the data. YF and VJA interpreted the results, and YF wrote the manuscript. All authors read and approved the final version of the manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Frost G: The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005). *Br J Cancer* 109: 1965-1973, 2013.
2. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. *Bull World Health Organ* 89: 716-724, 724A-724C, 2011.
3. Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. *Am J Ind Med* 49: 1-7, 2006.
4. Joshi TK and Gupta RK: Asbestos in developing countries: Magnitude of risk and its practical implications. *Int J Occup Med Environ Health* 17: 179-185, 2004.
5. Yap TA, Aerts JG, Popat S and Fennell DA: Novel insights into mesothelioma biology and implications for therapy. *Nat Rev Cancer* 17: 475-488, 2017.
6. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. *Cell* 136: 629-641, 2009.
7. Mattick JS: The genetic signatures of noncoding RNAs. *PLoS Genet* 5: e1000459, 2009.
8. Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP, Sorensen PH, Reaman G, Milos P, Arceci RJ, Thompson JF, *et al*: The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. *BMC Biol* 8: 149, 2010.
9. Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. *Mol Cancer* 10: 38, 2011.
10. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, Becker-Santos DD, MacAulay CE, Lam S, Brown CJ, *et al*: Human cancer long non-coding RNA transcriptomes. *PLoS One* 6: e25915, 2011.
11. Brosnan CA and Voinnet O: The long and the short of noncoding RNAs. *Curr Opin Cell Biol* 21: 416-425, 2009.
12. Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. *Nat Rev Genet* 10: 155-159, 2009.
13. Statello L, Guo CJ, Chen LL and Huarte M: Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol* 22: 96-118, 2021.
14. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, *et al*: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* 458: 223-227, 2009.
15. Costa FF: Non-coding RNAs: Meet thy masters. *BioEssays* 32: 599-608, 2010.
16. Huarte M and Rinn JL: Large non-coding RNAs: Missing links in cancer? *Hum Mol Genet* 19: R152-R161, 2010.
17. Cui M, You L, Ren X, Zhao W, Liao Q and Zhao Y: Long non-coding RNA *PVTI* and cancer. *Biochem Biophys Res Commun* 471: 10-14, 2016.
18. Wang D and Hu Y: Long Non-coding RNA *PVTI* Competitively Binds MicroRNA-424-5p to Regulate CARM1 in Radiosensitivity of Non-Small-Cell Lung Cancer. *Mol Ther Nucleic Acids* 16: 130-140, 2019.

19. Hu J, Han Q, Gu Y, Ma J, McGrath M, Qiao F, Chen B, Song C and Ge Z: Circular RNA *PVTI* expression and its roles in acute lymphoblastic leukemia. *Epigenomics* 10: 723-732, 2018.
20. Guo J, Hao C, Wang C and Li L: Long noncoding RNA *PVTI* modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2. *Cancer Cell Int* 18: 98, 2018.
21. Zhang R, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W and Liu Y: Long Noncoding RNA Plasmacytoma Variant Translocation 1 (*PVTI*) Promotes Colon Cancer Progression via Endogenous Sponging miR-26b. *Med Sci Monit* 24: 8685-8692, 2018.
22. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, *et al*: Amplification of *PVTI* contributes to the pathophysiology of ovarian and breast cancer. *Clin Cancer Res* 13: 5745-5755, 2007.
23. Yang Q, Yu Y, Sun Z and Pan Y: Long non-coding RNA *PVTI* promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer. *Biomed Pharmacother* 106: 61-67, 2018.
24. Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, *et al*: Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma. *Am J Surg Pathol* 41: 1045-1052, 2017.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, *et al*: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 492: 290, 2012.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. *Methods* 25: 402-408, 2001.
27. Gebäck T, Schulz MM, Koumoutsakos P and Detmar M: TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays. *Biotechniques* 46: 265-274, 2009.
28. Lamprecht MR, Sabatini DM and Carpenter AE: CellProfiler: Free, versatile software for automated biological image analysis. *Biotechniques* 42: 71-75, 2007.
29. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, Gennaro V, Romanelli A, Chellini E, Pascucci C, *et al*: Survival of pleural malignant mesothelioma in Italy: A population-based study. *Int J Cancer* 124: 201-207, 2009.
30. Cao C, Tian D, Park J, Allan J, Pataky KA and Yan TD: A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. *Lung Cancer* 83: 240-245, 2014.
31. Bunch H: Gene regulation of mammalian long non-coding RNA. *Mol Genet Genomics* 293: 1-15, 2018.
32. Chi Y, Wang D, Wang J, Yu W and Yang J: Long Non-Coding RNA in the Pathogenesis of Cancers. *Cells* 8: 1015, 2019.
33. Wright CM, Kirschner MB, Cheng YY, O'Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, *et al*: Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). *PLoS One* 8: e70940, 2013.
34. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A and Wistuba II: Frequent coamplification and cooperation between C-MYC and *PVTI* oncogenes promote malignant pleural mesothelioma. *J Thorac Oncol* 9: 998-1007, 2014.
35. Yang A, Wang H and Yang X: Long non-coding RNA *PVTI* indicates a poor prognosis of glioma and promotes cell proliferation and invasion via target EZH2. *Biosci Rep* 37: BSR20170871, 2017.
36. Fei BY, He X, Ma J, Zhang M and Chai R: *FOXMI* is associated with metastasis in colorectal cancer through induction of the epithelial-mesenchymal transition. *Oncol Lett* 14: 6553-6561, 2017.
37. Shi C and Zhang Z: MicroRNA-320 suppresses cervical cancer cell viability, migration and invasion via directly targeting *FOXMI*. *Oncol Lett* 14: 3809-3816, 2017.
38. Zhang J, Chen XY, Huang KJ, Wu WD, Jiang T, Cao J, Zhou LS, Qiu ZJ and Huang C: Expression of *FOXMI* and the EMT-associated protein E-cadherin in gastric cancer and its clinical significance. *Oncol Lett* 12: 2445-2450, 2016.
39. Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, *et al*: *FOXMI* expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. *J Exp Clin Cancer Res* 36: 63, 2017.
40. Zhang H, Zhong H, Li L, Ji W and Zhang X: Overexpressed transcription factor *FOXMI* contributes to the progression of colorectal cancer. *Mol Med Rep* 13: 2696-2700, 2016.
41. Zhang J, Niu Y and Huang C: Role of *FOXMI* in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer. *Recent Patents Anticancer Drug Discov* 12: 247-259, 2017.
42. Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, Shi J, Gong XD, Zhu YL, Liu F, *et al*: Overexpression of *FOXMI* is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. *Oncol Rep* 31: 2660-2668, 2014.
43. Li M, Chi C, Zhou L, Chen Y and Tang X: Circular *PVTI* regulates cell proliferation and invasion via miR-149-5p/*FOXMI* axis in ovarian cancer. *J Cancer* 12: 611-621, 2021.
44. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni SJ, Dong L, Yang Y, *et al*: A Positive Feedback Loop of lncRNA-*PVTI* and *FOXMI* Facilitates Gastric Cancer Growth and Invasion. *Clin Cancer Res* 23: 2071-2080, 2017.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.